This review examines mitochondrial pathology as the central orchestrator of SIC progression and integrates mitochondrial biology, immunometabolism, and translational medicine to identify promising directions for improving patient outcomes.
Linghong Xu, Jun Zhang, Huijing Tong et al.· Frontiers in Cardiovascular...· 0 citations
Oxidative stress and mitochondrial dysfunction were intimately linked processes driving aging and numerous human diseases. Mitochondria generating reactive oxygen species (ROS) during energy metabolism; physiological ROS levels are vital for cell signaling and adaptation. However, excessive ROS damage mitochondrial DNA...
A. Abdulkader, A. M. Hussein· World Journal of Chemical an...· 0 citations
This review emphasizes not only mechanistic advances but also conflicting findings, model limitations, and the barriers that currently separate experimental efficacy from clinically meaningful CKD outcomes.
F. De Luca, Dario Troise, Valentina Camporeale et al.· Antioxidants· 1 citation
This review systematically summarizes the mechanisms of MQC dysregulation in metabolic diseases, the evidence supporting natural small-molecule interventions, and strategies for formulation and delivery optimization.
Doxorubicin (DOX) is a broad-spectrum anthracycline chemotherapeutic agent, and its clinical application is severely limited by dose-dependent cardiotoxicity (DIC), for which there are currently no effective clinical interventions. Mitochondria are the central organelles regulating myocardial energy metabolism and cell...
Xin-Yu Xue, Xi-Han Liao, Xing Ji et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.